Aclaris Therapeutics, Inc. (ACRS): Cash & Equivalents
$19.96M
As of 2025-12-31
$19.17M
As of 2026-06-30
-23.9%
3-year compound annual growth
-2.0%
5-year compound annual growth
+7.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.96M | -18.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $24.57M | -38.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $39.88M | -11.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $45.28M | +65.6% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $27.35M | +24.0% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $22.06M | -35.5% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $34.19M | n/a | 2021-02-25, Balance as of period end |
| No annual figure between 2017-12-31 and 2019-12-31. | |||
| 2017-12-31 | $20.20M | -33.0% | 2018-03-12, Balance as of period end |
| 2016-12-31 | $30.17M | +206.3% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $9.85M | -8.4% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $10.76M | +12.2% | 2017-03-15, Balance as of period end |
| 2013-12-31 | $9.59M | n/a | 2016-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
| Adagene Inc. (ADAG) | 2025-12-31 | $74.52M | -12.5% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $199.16M | +39.6% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $1.42B | -47.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $653.48M | +355.9% |
Compare ACRS, COYA, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗